Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market
- 2020年04月24日 19:37:00
- テクノロジー
- JCN Newswire
Efficient R&D Platform and Strong R&D Strength
The Company is dedicated to finding solutions to treat tumors and immunological diseases. It is generally known that it takes years to develop a new drug. However, the Company has over 20 drug development programs developed in-house though it has been established for only eight years. These programs include 12 antibodies in clinical-stage development, six bi-specific antibodies (two of which are at the clinical stage), and four antibodies with IND approvals from the Food and Drug Administration (FDA). Its product pipelines cover several major diseases, such as tumors, immunological diseases, and cardiovascular diseases. It is worth mentioning that the Company has developed all its programs in-house. In November 2015, the Company became the first China-based biotech company to out-license a fully internally discovered monoclonal antibody to a world-leading pharmaceutical company as it out-licensed its CTLA-4 monoclonal antibody drug candidate (AK107) to Merck for a total consideration of up to USD200 million.
The Company's strong R&D capability is indispensable from its end-to-end ACE Platform that possesses comprehensive, the most cutting-edge functionalities in developing therapeutic antibodies. The ACE Platform encompasses drug development and manufacturing and enables seamless technology transfer from drug discovery and CMC to manufacturing. Moreover, it holds strong internal manufacturing capacity that is compliant with GMP standards regulated by the NMPA, FDA and EMA. All drugs in the clinical stage are produced in the Company's proprietary facilities in line with GMP standards.
Prominent Advantages of Core Products, Favored by the Capital Market
The key to biopharmaceutical success lies in R&D strength and efficiency. The player who takes the lead to develop a drug and obtain approval for launch, and who can prove commercialization capabilities will gain competitive edges.
The Company has developed industry-leading drugs with the ACE Platform including its core products: PD-1/CTLA-4 bi-specific antibody (AK104) and PD-1 monoclonal antibody drug, Penpulimab (AK105). Its products also encompass AK101, a promising monoclonal antibody against autoimmune diseases, and AK102 that has high potential to become the first cardiovascular drug candidate against PCSK9 developed in China.
The Company has led the world in terms of the R&D of bi-specific antibodies. Bi-specific antibodies are deemed as a second-generation antibody therapy against tumors. With respect to the research on bi-specific antibodies, the Company possesses the unique bifunctional antibody technology, Tetrabody, making it one of the few bi-specific antibody platforms verified in both manufacturing and clinical stage. According to clinical observation, compared with the combined therapy of Nivolumab and Ipilimumab, AK104 has demonstrated better safety and efficacy. As of September 30, 2019, over 90 bi-specific antibodies were undergoing clinic trial. Nevertheless, no PD-(L)-based bi-specific antibodies had been approved for market launch. AK104 is the world's first bi-specific antibody drug that is in the clinical trial stage. It is expected that the first new drug application (NDA) of AK104 of the Company for treating cervical cancer will result in first-mover advantage.
AK105 of the Company is a monoclonal antibody currently in late-stage clinical development. PD-1 monoclonal antibody drugs are experiencing fierce competition, as six PD-1 drugs have been launched in China. Despite the extensively competitive market, AK105 is still favored for its strong efficacy and high safety. Therefore, Sino Biopharmaceutical Limited, a HK-listed pharmaceutical leader, has cooperated with the Company to jointly develop and commercialize AK105. AK105 of the Company is the only PD-1 antibody that Sino Biopharm can use to develop PD-1-based monotherapy or combination therapy, which evidences the great commercial potential of AK105. After the new drug is launched, the wide online sale channels and immense commercial capability of Sino Biopharmaceutical Limited will be utilized by the Company to maximize the commercial value of AK105.
Thanks to its strong R&D strength and commercialization capabilities, the Company has been favored by the capital market. Through Series D financing in November last year, the Company raised USD126 million in total, with the leading investor being Sino Biopharmaceutical Limited. Medical funds like Lake Bleu Capital, OrbiMed, and AIHC Capital participated in the financing. The Company's valuation reached USD836 million after Series D financing and became nearly 18 times as high as that after Series A financing of RMB330 million in just four years. Especially, Shenzhen Capital Group Co., Ltd. (SCGC), a leading venture capital firm in China that was co-founded by the Shenzhen Municipal Government and a group of private partners, participated in every series of financing. Relevant funds under K. Wah Group became a shareholder of Akeso in the series of financing before the IPO. This also means that K. Wah Group has set foot in the healthcare sector. Investment from famous capital holders reflect Akeso's bright future.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
宮迫博之の長男、“父の因縁”チバテレ出演で謝罪「いくつやれば気が済むのか…」
少女にみだらな行為で逮捕…38歳俳優が謝罪も「僕はまだ、表現者として生きたい」活動継続へ
玉川徹氏、大谷翔平は「二刀流は魅力だけど3冠王はすごい」長嶋一茂「今年は安心して見られる」
ヤリスは「X」で十分か、徹底検証!おすすめグレードも解説
山田涼介は「言えば何でもくれます」…姉さん女優の猛攻に「やめろよ」とタジタジ
Amazonプライムデーで最大6.5%を得る方法 ドコモユーザー必見!ビッグセールで得するために忘れてはいけない下準備
沖縄アクターズスクール創業者・マキノ正幸さん死去 安室奈美恵さんや、DA PUMPなど輩出
事務所業務停止の酒井若菜、アービングへの所属を発表「この半年、とても。苦しかったです」
「自分勝手で奔放でめちゃくちゃな人でしたw」牧野アンナさん、父マキノ正幸さんの思い出語る
テレ東退社の松丸友紀「人力舎」所属wo発表「初心にかえって一歩一歩進んでまいります」
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
「あまりにもデカすぎる…」三田悠貴、迫力バスト際立つ小面積ビキニショットにネット騒然
【ネタバレ?】史実で見るキングダムの今後の展開まとめ〜中華統一までの全体像
丸亀製麺の「丸亀うどーなつ」が販売開始で完売店舗続出!過去の「うどんで作ったドーナッツ」と比較すると……
ひまそらあかねを無視するマスコミ、岩下の新生姜社長が名前を出すだけで「不買運動」が叫ばれる事態に
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
「エロい」42歳山川恵里佳、白ビキニのオフショ動画4連発!20年ぶりグラビア復帰「最ッ高」
中国・日本人母子刺傷 止めに入ったバス案内係の中国人女性死亡
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
株主優待の桐谷さん「アダルトサイトを見てたらウィルス感染」正直投稿 修復のお礼はやはり…
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
【ネタバレ?】史実で見るキングダムの今後の展開まとめ〜中華統一までの全体像
ガーシーが綾野剛のLINE公開でネット騒然「ショック」「すごいエンタメ」
イケメンだから許される!堀北真希と山本耕史の「馴れ初め」が映画化希望するレベル
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
「愛が生まれた日」藤谷美和子(56)の現在がヤバい!?徘徊生活を送っていた過去も明らかに。
柏原崇(45)現在を調べてみた結果、相変わらずかっこよすぎた!
都知事選掲示板にヌードポスター ひろゆき氏「世も末」 SNSで批判噴出
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
![game_banner](/images/banner-game.png)
宮迫博之の長男、“父の因縁”チバテレ出演で謝罪「いくつやれば気が済むのか…」
少女にみだらな行為で逮捕…38歳俳優が謝罪も「僕はまだ、表現者として生きたい」活動継続へ
玉川徹氏、大谷翔平は「二刀流は魅力だけど3冠王はすごい」長嶋一茂「今年は安心して見られる」
ヤリスは「X」で十分か、徹底検証!おすすめグレードも解説
山田涼介は「言えば何でもくれます」…姉さん女優の猛攻に「やめろよ」とタジタジ
Amazonプライムデーで最大6.5%を得る方法 ドコモユーザー必見!ビッグセールで得するために忘れてはいけない下準備
沖縄アクターズスクール創業者・マキノ正幸さん死去 安室奈美恵さんや、DA PUMPなど輩出
事務所業務停止の酒井若菜、アービングへの所属を発表「この半年、とても。苦しかったです」
「自分勝手で奔放でめちゃくちゃな人でしたw」牧野アンナさん、父マキノ正幸さんの思い出語る
テレ東退社の松丸友紀「人力舎」所属wo発表「初心にかえって一歩一歩進んでまいります」